Free Trial
NASDAQ:GNLX

Genelux (GNLX) Stock Price, News & Analysis

Genelux logo
$3.51 +0.12 (+3.54%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.56 +0.05 (+1.28%)
As of 08/1/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Genelux Stock (NASDAQ:GNLX)

Key Stats

Today's Range
$3.32
$3.56
50-Day Range
$2.45
$3.60
52-Week Range
$1.60
$5.89
Volume
66,738 shs
Average Volume
155,977 shs
Market Capitalization
$132.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.75
Consensus Rating
Buy

Company Overview

Genelux Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

GNLX MarketRank™: 

Genelux scored higher than 35% of companies evaluated by MarketBeat, and ranked 727th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genelux has only been the subject of 2 research reports in the past 90 days.

  • Read more about Genelux's stock forecast and price target.
  • Earnings Growth

    Earnings for Genelux are expected to decrease in the coming year, from ($0.88) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genelux is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genelux is -3.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Genelux has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Genelux's valuation and earnings.
  • Percentage of Shares Shorted

    7.07% of the float of Genelux has been sold short.
  • Short Interest Ratio / Days to Cover

    Genelux has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genelux has recently decreased by 0.43%, indicating that investor sentiment is improving.
  • Dividend Yield

    Genelux does not currently pay a dividend.

  • Dividend Growth

    Genelux does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.07% of the float of Genelux has been sold short.
  • Short Interest Ratio / Days to Cover

    Genelux has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Genelux has recently decreased by 0.43%, indicating that investor sentiment is improving.
  • News Sentiment

    Genelux has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Genelux this week, compared to 1 article on an average week.
  • Search Interest

    6 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genelux insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.30% of the stock of Genelux is held by insiders.

  • Percentage Held by Institutions

    Only 37.33% of the stock of Genelux is held by institutions.

  • Read more about Genelux's insider trading history.
Receive GNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter.

GNLX Stock News Headlines

This Social Security Shift Could Boost Benefits by 400%
If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.
Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX)
See More Headlines

GNLX Stock Analysis - Frequently Asked Questions

Genelux's stock was trading at $2.36 at the beginning of the year. Since then, GNLX stock has increased by 48.7% and is now trading at $3.51.

Genelux Corporation (NASDAQ:GNLX) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03.

Genelux (GNLX) raised $16 million in an initial public offering (IPO) on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO.

Top institutional shareholders of Genelux include Woodward Diversified Capital LLC (4.71%), LifeSteps Financial Inc. (0.26%), Falcon Wealth Planning (0.06%) and Beacon Capital Management LLC (0.05%). Insiders that own company stock include Aladar Szalay, John Thomas, Sean Ryder, Caroline Jewett, Thomas Zindrick, Yong Yu, John W Smither, Joseph Cappello, Doug Samuelson and Qian Zhang.
View institutional ownership trends
.

Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/08/2025
Today
8/02/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GNLX
CIK
1231457
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$30.00
Low Price Target
$8.00
Potential Upside/Downside
+405.7%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.87 million
Net Margins
N/A
Pretax Margin
-373,362.47%
Return on Equity
-93.04%
Return on Assets
-74.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.67
Quick Ratio
4.67

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.76 per share
Price / Book
4.62

Miscellaneous

Outstanding Shares
37,761,000
Free Float
34,249,000
Market Cap
$132.54 million
Optionable
Not Optionable
Beta
-0.34

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:GNLX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners